title: The ongoing evolution of antibody-based treatments for Ebola virus infection.
abstract: The 2014-2016 Ebola virus outbreak in West Africa was the deadliest in history, prompting the evaluation of various drug candidates, including antibody-based therapeutics for the treatment of Ebola hemorrhagic fever (EHF). Prior to 2014, only convalescent blood products from EHF survivors had been administered to newly infected individuals as a form of treatment. However, during the recent outbreak, monoclonal antibody cocktails such as ZMapp, ZMAb and MB-003 were either tested in a human clinical safety and efficacy trial or provided to some based on compassionate grounds. This review aims to discuss the evolution of antibody-based treatments for EHF, their clinical trial efficacy and the development of new antibody-based therapies currently advancing in preclinical testing.
authors.affiliation: Zoonotic Diseases & Special Pathogens, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada.|Department of Immunology, University of Manitoba, Winnipeg, MB, Canada.
authors.forename: Emelissa J
authors.initials: EJ
authors.lastname: Mendoza
authors.affiliation: Zoonotic Diseases & Special Pathogens, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada.|Department of Medical Microbiology, University of Manitoba, Winnipeg, MB, Canada.
authors.forename: Trina
authors.initials: T
authors.lastname: Racine
authors.affiliation: Department of Medical Microbiology, University of Manitoba, Winnipeg, MB, Canada.|Department of Pathology & Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.|Département de Microbiologie-Infectiologie et D'immunologie, Université Laval, 2705 Boulevard Laurier, Quebec City, QC G1V4G2, Canada.
authors.forename: Gary P
authors.initials: GP
authors.lastname: Kobinger
mesh_terms: D000354:Africa, Western; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000914:Antibodies, Viral / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D029043:Ebolavirus / Q000276:immunology*; D019142:Hemorrhagic Fever, Ebola / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral
keywords: Ebola virus; convalescent plasma; monoclonal antibodies; outbreak; pan-ebolavirus; pan-filovirus; therapeutics;  clinical trials